Targeted Network Meeting
Experimental medicine and brain disorders: the agenda for 2016 and beyond

coordinators: Gerard R. Dawson, United Kingdom
David Nutt, United Kingdom
Wednesday 2 September 2015

08:00 - 15:00

08:00 - 09:45 Genetic influences in patient stratification and experimental medicine for brain disorder
 chair: J.F. William Deakin, United Kingdom
08:00 - 08:30Implications of new genetics for experimental medicine and patient stratification
 speaker: Anna Need, United Kingdom
08:30 - 09:00Impact of new genetics on drug design, development and trial
 speaker: Alan Cross, United States
09:00 - 09:30What does cross species research tell us about brain disorders?
 speaker: Jeffrey Glennon, Netherlands, The
09:30 - 09:45Discussion
09:45 - 10:15Break
10:15 - 12:00The experimental medicine agenda for industry 2016 and beyond
 chair: Gerard R. Dawson, United Kingdom
10:15 - 10:45Challenges in quantifying neurosymptomatic approaches in the clinic
 speaker: Darrel Pemberton, Belgium
10:45 - 11:15How can industry use fMRI to stratify patients and discover new treatments?
 speaker: Andreas Meyer-Lindenberg, Germany
11:15 - 11:45Translation has to reverse before it can go forward
 speaker: Hugh M. Marston, Germany
11:45 - 12:00Discussion
12:00 - 13:00Lunch
13:00 - 14:30Anticipated training needs for a new era of experimental medicine
 chair: Hamish McAllister-Williams, United Kingdom
13:00 - 13:45Future skill needs for industry
 speaker: S√łgaard, Birgitte
13:45 - 14:30Future skill needs for academia
 speaker: Hamish McAllister-Williams, United Kingdom
14:30 - 14:45Discussion
14:45 - 15:00General discussion and closing